Murid_NP Herpesvirus_NP 4_CD Strain_NP 68_CD M2_NP Protein_NP Is_VBZ a_DT B-Cell-Associated_JJ Antigen_NN Important_JJ for_IN Latency_NP but_CC Not_RB Lymphocytosis_NN This_DT work_NN describes_VBZ analyses_NNS of_IN the_DT function_NN of_IN the_DT murid_JJ herpesvirus_NN 4_CD strain_NN 68_CD (_( MHV-68_NP )_) M2_NP gene_NN ._SENT A_DT frameshift_NN mutation_NN was_VBD made_VBN in_IN the_DT M2_JJ open_JJ reading_NN frame_NN that_WDT caused_VBD premature_JJ termination_NN of_IN translation_NN of_IN M2_NP after_IN amino_NN acid_NN residue_NN 90_CD ._SENT The_DT M2_NP mutant_NN showed_VBD no_DT defect_NN in_IN productive_JJ replication_NN in_IN vitro_NN or_CC in_IN lungs_NNS after_IN infection_NN of_IN mice_NNS ._SENT Likewise_RB ,_, the_DT characteristic_JJ transient_JJ increase_NN in_IN spleen_NN cell_NN number_NN ,_, Vbeta4_NP T-cell-receptor-positive_NP CD8+_NP T-cell_NN mononucleosis_NN ,_, and_CC establishment_NN of_IN latency_NN were_VBD unaffected_JJ ._SENT However_RB ,_, the_DT M2_NP mutant_JJ virus_NN was_VBD defective_JJ in_IN its_PP$ ability_NN to_TO cause_VB the_DT transient_JJ sharp_JJ rise_NN in_IN latently_RB infected_JJ cells_NNS normally_RB seen_VBN in_IN the_DT spleen_NN after_IN infection_NN of_IN mice_NNS ._SENT We_PP also_RB demonstrate_VBP that_DT expression_NN of_IN M2_NP is_VBZ restricted_VBN to_TO B_NP cells_NNS in_IN the_DT spleen_NN and_CC that_IN M2_NP encodes_VBZ a_DT 30-kDa_JJ protein_NN localizing_VBG predominantly_RB in_IN the_DT cytoplasm_NN and_CC plasma_NN membrane_NN of_IN B_NP cells_NNS ._SENT Murid_NP herpesvirus_NP 4_CD is_VBZ an_DT endogenous_JJ pathogen_NN of_IN free-living_JJ rodents_NNS of_IN the_DT Apodemus_NP genus_NN ,_, e.g._FW ,_, wood_NN mice_NNS ._SENT Infection_NN of_IN laboratory_NN mice_NNS by_IN murid_JJ herpesvirus_NN 4_CD strain_NN 68_CD (_( MHV-68_NP ;_: also_RB called_VBN gammaHV-68_NN )_) is_VBZ an_DT amenable_JJ model_NN system_NN for_IN the_DT study_NN of_IN gammaherpesvirus_NN pathogenesis_NN and_CC for_IN the_DT development_NN of_IN therapeutic_JJ strategies_NNS against_IN these_DT viruses_NNS ._SENT Following_VBG intranasal_JJ inoculation_NN of_IN mice_NNS with_IN MHV-68_NP ,_, a_DT productive_JJ infection_NN occurs_VBZ in_IN the_DT lung_NN ._SENT This_DT is_VBZ cleared_VBN around_IN day_NN 10_CD postinfection_NN (_( p.i._JJ )_) by_IN CD8+_NP T_NN cells_NNS ,_, though_IN the_DT virus_NN persists_VBZ in_IN a_DT latent_JJ form_NN in_IN epithelial_JJ cells_NNS at_IN this_DT site_NN ._SENT MHV-68_NP spreads_VBZ to_TO the_DT spleen_NN ,_, where_WRB it_PP also_RB becomes_VBZ latent_JJ ,_, predominantly_RB within_IN B_NP lymphocytes_NNS ,_, but_CC also_RB in_IN macrophages_NNS and_CC dendritic_JJ cells_NNS ._SENT Establishment_NN of_IN latency_NN in_IN the_DT spleen_NN is_VBZ associated_VBN with_IN a_DT marked_JJ splenomegaly_NN ,_, increase_NN in_IN lymphocytes_NNS in_IN the_DT spleen_NN (_( splenic_JJ lymphocytosis_NN )_) ,_, and_CC a_DT subsequent_JJ peripheral_JJ mononucleosis_NN that_WDT resembles_VBZ that_IN caused_VBN by_IN primary_JJ infection_NN of_IN humans_NNS by_IN Epstein-Barr_NP virus_NN (_( EBV_NP )_) ._SENT Splenic_JJ lymphocytosis_NN ,_, which_WDT peaks_VBZ at_IN day_NN 14_CD p.i._NN ,_, is_VBZ driven_VBN by_IN CD4+_NP T_NN cells_NNS and_CC is_VBZ dependent_JJ on_IN MHV-68-infected_NP B_NP cells_NNS in_IN the_DT spleen_NN ._SENT Concomitant_JJ with_IN the_DT lymphocytosis_NN is_VBZ a_DT sharp_JJ rise_NN in_IN the_DT number_NN of_IN latently_RB infected_JJ B_NP cells_NNS ,_, the_DT resolution_NN of_IN which_WDT to_TO a_DT relatively_RB constant_JJ baseline_NN level_NN is_VBZ achieved_VBN by_IN CD8+_NP T_NN cells_NNS ._SENT CD8+_JJ T_NN cells_NNS along_IN with_IN antibody_NN are_VBP important_JJ in_IN the_DT long-term_JJ control_NN of_IN persistent_JJ infection_NN ._SENT Mononucleosis_NN peaks_NNS at_IN around_IN day_NN 35_CD p.i._NN and_CC is_VBZ characterized_VBN by_IN the_DT massive_JJ expansion_NN of_IN a_DT diverse_JJ CD8+_NP T-cell_NN population_NN expressing_VBG the_DT Vbeta4_NP T-cell_NN receptor_NN (_( TCR_NP )_) chain_NN in_IN conjunction_NN with_IN a_DT variety_NN of_IN TCR_NP alpha_NN chains_NNS ._SENT This_DT differs_VBZ from_IN both_DT EBV-associated_JJ mononucleosis_NN and_CC classical_JJ superantigen_NN reactions_NNS in_IN that_WDT the_DT majority_NN of_IN T_NN cells_NNS are_VBP not_RB largely_RB virus_NN specific_JJ ,_, nor_CC is_VBZ their_PP$ expansion_NN major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) dependent_JJ ._SENT However_RB ,_, the_DT Vbeta4+_NP T-cell_NN expansion_NN is_VBZ dependent_JJ upon_IN the_DT presence_NN of_IN MHV-68-infected_NP B_NP cells_NNS and_CC CD40_JJ ligand-dependent_JJ CD4+_NP T-cell_NN help_NN ._SENT The_DT left_VBN end_NN of_IN the_DT unique_JJ region_NN of_IN the_DT MHV-68_NP genome_NN has_VBZ attracted_VBN considerable_JJ interest_NN due_JJ to_TO the_DT presence_NN of_IN four_CD open_JJ reading_NN frames_NNS (_( ORFs_NP )_) (_( M1_NP ,_, M2_NP ,_, M3_NP ,_, and_CC M4_NP )_) and_CC eight_CD viral_JJ tRNA-like_JJ genes_NNS (_( vtRNAs_NNS )_) ,_, none_NN of_IN which_WDT have_VBP a_DT homologue_NN in_IN other_JJ gammaherpesvirus_NN genomes_NNS ._SENT M2_NP has_VBZ attracted_VBN particular_JJ interest_NN because_IN its_PP$ expression_NN is_VBZ restricted_VBN to_TO latent_JJ infection_NN in_IN vitro_NN and_CC in_IN vivo_RB ,_, where_WRB the_DT peak_NN of_IN expression_NN occurs_VBZ around_IN day_NN 14_CD p.i._NN in_IN the_DT spleen_NN (_( i.e._FW ,_, during_IN splenomegaly_NN )_) ,_, consistent_JJ with_IN a_DT role_NN in_IN the_DT establishment_NN of_IN latency_NN ._SENT The_DT 193-amino-acid_JJ M2_JJ protein_NN ,_, furthermore_RB ,_, contains_VBZ an_DT actively_RB recognized_VBN CD8+_NP T-cell_NN epitope_NN ,_, suggesting_VBG that_IN immune_JJ regulation_NN of_IN M2-expressing_NP cells_NNS is_VBZ critical_JJ for_IN the_DT resolution_NN of_IN splenomegaly_NN and_CC maintenance_NN of_IN the_DT host-virus_NN equilibrium_NN that_WDT underlies_VBZ viral_JJ persistence_NN ._SENT All_DT molecular_JJ ,_, cellular_JJ ,_, biological_JJ ,_, and_CC virological_JJ techniques_NNS were_VBD performed_VBN exactly_RB as_RB described_VBN in_IN detail_NN by_IN Macrae_NP et_FW al._FW unless_IN otherwise_RB specified_VBN ._SENT To_TO assess_VB the_DT function_NN of_IN M2_NP ,_, we_PP generated_VBD a_DT recombinant_JJ virus_NN with_IN a_DT 4-bp_JJ deletion_NN in_IN the_DT M2_NP ORF_NP ._SENT To_TO generate_VB the_DT recombinant_JJ ,_, we_PP used_VBD a_DT modification_NN of_IN a_DT technique_NN that_IN we_PP had_VBD developed_VBN for_IN rescue_NN of_IN wild-type_NN (_( MHV-68_NP )_) virus_NN from_IN the_DT defective_JJ MHV-76_NP strain_NN ._SENT Here_RB ,_, the_DT 9.5-kbp_NN deletion_NN at_IN the_DT left_VBN end_NN of_IN the_DT unique_JJ region_NN of_IN the_DT MHV-76_NP genome_NN (_( relative_JJ to_TO MHV-68_NP )_) was_VBD repaired_VBN by_IN homologous_JJ recombination_NN with_IN a_DT cosmid_JJ (_( cA8_NN )_) that_WDT contains_VBZ the_DT relevant_JJ region_NN from_IN the_DT wild-type_JJ MHV-68_NP genome_NN (_( nucleotide_NN sequence_NN 115165_CD to_TO 26842_CD )_) ._SENT To_TO construct_VB such_PDT a_DT recombinant_JJ MHV-68_NP (_( rescuant_NN )_) with_IN a_DT lesion_NN in_IN the_DT M2_JJ gene_NN ,_, we_PP utilized_VBD a_DT SalI_NP restriction_NN site_NN at_IN genome_NN coordinate_VB 4337_CD that_WDT is_VBZ unique_JJ within_IN cA8_NN to_TO generate_VB a_DT 4-bp_JJ deletion_NN within_IN the_DT M2_NP ORF_NP ._SENT This_DT deletion_NN caused_VBD a_DT frameshift_NN that_WDT would_MD result_VB in_IN premature_JJ termination_NN of_IN translation_NN after_IN amino_NN acid_NN residue_NN 90_CD and_CC mutated_VBD the_DT known_VBN cytotoxic_JJ T-cell_NN epitope_NN in_IN M2_NP ._SENT Specifically_RB ,_, following_VBG restriction_NN with_IN SalI_NP (_( Invitrogen_NP )_) ,_, cA8_NN was_VBD digested_VBN with_IN mung_JJ bean_NN nuclease_NN (_( Invitrogen_NP )_) to_TO remove_VB the_DT 5_CD '_POS overhang_NN and_CC then_RB religated_JJ to_TO generate_VB cA8DeltaM2_NN ._SENT To_TO ensure_VB that_IN the_DT predicted_VBN frameshift_NN mutation_NN had_VBD been_VBN introduced_VBN ,_, cosmids_NNS that_WDT lacked_VBD a_DT HincII_NP restriction_NN site_NN within_IN the_DT targeted_JJ SalI_NP site_NN were_VBD identified_VBN and_CC subjected_VBN to_TO DNA_NP sequence_NN analysis_NN ._SENT To_TO generate_VB recombinant_JJ virus_NN ,_, BHK-21_NP cells_NNS were_VBD cotransfected_VBN with_IN cA8DeltaM2_JJ targeting_VBG vector_NN and_CC MHV-76_NP DNA_NP as_RB described_VBD previously_RB ,_, and_CC the_DT resulting_VBG plaques_NNS containing_VBG MHV_NP with_IN the_DT reinserted_JJ 9.5-kbp_NN DNA_NN fragment_NN containing_VBG the_DT M2_JJ mutation_NN [_SYM 76(RDeltaM2)_NP ]_SYM were_VBD identified_VBN by_IN PCR_NP with_IN primers_NNS that_WDT amplified_VBD M2_NP ._SENT A_DT wild-type_JJ rescuant_NN [_SYM 76(WTR)_NP ]_SYM containing_VBG the_DT intact_JJ M2_NP gene_NN was_VBD similarly_RB generated_VBN with_IN cA8_NN instead_RB of_IN cA8DeltaM2_NN ._SENT After_IN five_CD rounds_NNS of_IN plaque_NN purification_NN by_IN limiting_VBG dilution_NN ,_, recombinant_JJ virus_NN was_VBD characterized_VBN by_IN Southern_NP blot_NN hybridization_NN and_CC PCR_NP analysis_NN to_TO ensure_VB that_IN it_PP was_VBD free_JJ of_IN contaminating_VBG MHV-76_NP ._SENT The_DT presence_NN and_CC integrity_NN of_IN the_DT M2_NP and_CC mutated_VBD M2_NP ORF_NP were_VBD first_RB tested_VBN by_IN restriction_NN digestion_NN of_IN infected-cell_NN DNA_NN with_IN HincII_NP followed_VBD by_IN Southern_NP blot_NN hybridization_NN with_IN the_DT M2_NP ORF_NP as_IN a_DT probe_NN ._SENT The_DT results_NNS showed_VBD the_DT presence_NN of_IN the_DT expected_VBN 2.2-kbp_JJ and_CC 354-bp_JJ HincII_NP fragments_NNS in_IN the_DT wild-type_NN rescuant_NN 76(WTR)_NP (_( the_DT expected_VBN 58-bp_JJ fragment_NN was_VBD too_RB small_JJ to_TO be_VB visualized_VBN on_IN the_DT blot_NN )_) ._SENT In_IN 76(RDeltaM2)_JJ DNA_NN the_DT expected_VBN 2.2-kbp_JJ fragment_NN was_VBD present_JJ ,_, and_CC the_DT 354-bp_JJ fragment_NN had_VBD been_VBN replaced_VBN by_IN the_DT predicted_VBN fragment_NN of_IN 412_CD bp_NN due_JJ to_TO the_DT deletion_NN of_IN the_DT HincII_NP site_NN at_IN position_NN 4337_CD and_CC amalgamation_NN of_IN the_DT 354-_CD and_CC 58-bp_JJ fragments_NNS ._SENT The_DT integrity_NN of_IN the_DT rest_NN of_IN the_DT leftmost_JJ unique_JJ portion_NN of_IN the_DT genome_NN was_VBD confirmed_VBN by_IN Southern_JJ analysis_NN of_IN HindIII-digested_JJ DNA_NN with_IN cA8_NN as_IN a_DT probe_NN and_CC by_IN PCR_NP analysis_NN for_IN M1_NP to_TO M4_NP ORFs_NP as_RB described_VBD by_IN Macrae_NP et_FW al._FW ._SENT Further_RBR ,_, the_DT gross_JJ integrity_NN of_IN the_DT genomes_NNS of_IN the_DT two_CD rescuant_JJ viruses_NNS was_VBD confirmed_VBN by_IN restriction_NN analysis_NN of_IN viral_JJ DNA_NN with_IN BamHI_NP ,_, HindIII_NP ,_, and_CC EcoRI_NP (_( data_NN not_RB shown_VBN )_) ._SENT Finally_RB ,_, the_DT integrity_NN of_IN the_DT 4-bp_JJ mutation_NN in_IN 76(RDeltaM2)_NP was_VBD confirmed_VBN by_IN sequencing_VBG the_DT DNA_NN obtained_VBN by_IN PCR_NP amplification_NN of_IN the_DT M2_NP ORF_NP ._SENT To_TO assess_VB potential_JJ effects_NNS of_IN the_DT mutation_NN in_IN M2_NP on_IN MHV-68_NP replication_NN ,_, we_PP performed_VBD single-step_VB virus_NN growth_NN curves_NNS (_( multiplicity_NN of_IN infection_NN [_SYM MOI_NP ]_SYM of_IN 5_CD )_) and_CC multistep_NN growth_NN curves_NNS (_( MOI_NP of_IN 0.01_CD )_) for_IN MHV-76_NP ,_, 76(WTR)_NP ,_, and_CC 76(RDeltaM2)_JJ in_IN BHK-21_JJ cells_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, all_DT three_CD viruses_NNS replicated_VBN with_IN similar_JJ efficiency_NN and_CC in_IN a_DT similar_JJ fashion_NN as_IN that_WDT reported_VBD previously_RB for_IN MHV-68_NP ._SENT This_DT result_NN was_VBD not_RB totally_RB unexpected_JJ ,_, since_IN M2_NP is_VBZ not_RB expressed_VBN to_TO any_DT great_JJ extent_NN during_IN productive_JJ MHV-68_NP infection_NN ,_, and_CC MHV-76_NP replicates_VBZ normally_RB in_IN tissue_NN culture_NN ._SENT Recent_JJ experiments_NNS by_IN Jacoby_NP et_FW al._FW ,_, furthermore_RB ,_, have_VBP yielded_VBN similar_JJ results_NNS with_IN respect_NN to_TO lack_NN of_IN a_DT contribution_NN by_IN M2_NP to_TO virus_NN replication_NN ._SENT The_DT influence_NN of_IN M2_NP on_IN productive_JJ infection_NN in_IN vivo_RB was_VBD assessed_VBN by_IN infecting_VBG groups_NNS of_IN BALB/c_NP mice_NNS with_IN MHV-76_NP ,_, 76(WTR)_NP ,_, and_CC 76(RDeltaM2)_JJ and_CC monitoring_VBG infectious_JJ virus_NN in_IN the_DT lungs_NNS at_IN various_JJ times_NNS p.i._JJ by_IN plaque_NN assay_NN ._SENT The_DT data_NNS in_IN Fig._NN demonstrated_VBD that_IN there_EX was_VBD no_DT significant_JJ quantitative_JJ difference_NN between_IN the_DT maximal_JJ titers_NNS achieved_VBN by_IN infectious_JJ wild-type_NN rescuant_NN 76(WTR)_NP (_( the_DT equivalent_NN of_IN MHV-68_NP )_) and_CC those_DT achieved_VBN by_IN MHV-76_NP ;_: however_RB ,_, MHV-76_NP was_VBD cleared_VBN slightly_RB more_RBR quickly_RB ._SENT By_IN contrast_NN ,_, the_DT yield_NN of_IN 76(RDeltaM2)_NP was_VBD minimally_RB but_CC significantly_RB higher_JJR than_IN that_DT of_IN either_DT MHV-76_NP or_CC 76(WTR)_NP (_( day_NN 5_CD ,_, P_NN <_SYM 0.001_CD )_) ,_, and_CC infectious_JJ virus_NN remained_VBD detectable_JJ through_IN day_NN 10_CD p.i._NN The_DT results_NNS obtained_VBN for_IN MHV-76_NP and_CC 76(WTR)_NP are_VBP similar_JJ to_TO those_DT reported_VBD previously_RB ._SENT Unexpectedly_RB ,_, the_DT mutation_NN in_IN M2_NP appeared_VBD to_TO slightly_RB enhance_VB virus_NN production_NN in_IN vivo_RB ._SENT The_DT reason_NN for_IN this_DT is_VBZ not_RB clear_JJ ,_, and_CC ,_, although_IN the_DT difference_NN was_VBD statistically_RB significant_JJ ,_, it_PP is_VBZ unlikely_JJ that_IN this_DT relative_JJ increase_NN in_IN titer_NN by_IN only_RB 1_CD log_NN over_IN 76(WTR)_NP in_IN the_DT context_NN of_IN a_DT 4.5-log_JJ titer_NN is_VBZ of_IN biological_JJ significance_NN ,_, particularly_RB given_VBN that_IN the_DT rate_NN of_IN clearance_NN of_IN 76(RDeltaM2)_NP from_IN the_DT lungs_NNS was_VBD similar_JJ to_TO that_DT of_IN 76(WTR_NP )_) ._SENT Recent_JJ experiments_NNS by_IN Jacoby_NP et_FW al._FW also_RB showed_VBD the_DT lack_NN of_IN a_DT contribution_NN of_IN M2_NP to_TO virus_NN replication_NN ._SENT Thus_RB ,_, M2_NP does_VBZ not_RB negatively_RB influence_VB virus_NN replication_NN upon_IN primary_JJ infection_NN ._SENT The_DT total_JJ number_NN of_IN splenic_JJ lymphocytes_NNS was_VBD determined_VBN in_IN mice_NNS at_IN various_JJ time_NN points_NNS after_IN infection_NN with_IN MHV-76_NP ,_, 76(WTR)_NP ,_, and_CC 76(RDeltaM2_JJ )_) ._SENT As_IN illustrated_VBN in_IN Fig._NN ,_, 76(WTR)_NP induced_VBD a_DT characteristic_JJ transient_JJ increase_NN in_IN splenic_JJ lymphocyte_NN number_NN that_WDT peaked_VBD at_IN day_NN 14_CD p.i._NP MHV-76_NP infection_NN also_RB caused_VBD an_DT increase_NN in_IN cellularity_NN ,_, but_CC cell_NN numbers_NNS were_VBD significantly_RB lower_JJR than_IN those_DT detected_VBN after_IN 76(WTR)_JJ infection_NN (_( day_NN 14_CD ,_, P_NN <_SYM 0.001_CD ;_: day_NN 21_CD ,_, P_NN <_SYM 0.01_CD )_) ._SENT In_IN contrast_NN ,_, 76(RDeltaM2)_NP induced_VBD a_DT transient_JJ increase_NN in_IN spleen_NN cell_NN number_NN of_IN similar_JJ intensity_NN and_CC duration_NN as_IN that_DT induced_VBN by_IN 76(WTR_NP )_) ._SENT Thus_RB ,_, the_DT mutation_NN in_IN M2_NP ,_, unlike_IN the_DT deletion_NN present_NN in_IN MHV-76_NP ,_, did_VBD not_RB affect_VB the_DT ability_NN of_IN MHV-68_NP to_TO cause_VB splenic_JJ lymphocytosis_NN ._SENT It_PP was_VBD possible_JJ ,_, however_RB ,_, that_IN even_RB though_IN the_DT mutation_NN in_IN M2_NP did_VBD not_RB influence_VB the_DT overall_JJ number_NN of_IN cells_NNS in_IN the_DT spleen_NN ,_, specific_JJ cell_NN subpopulations_NNS could_MD have_VB been_VBN affected_VBN ._SENT Therefore_RB ,_, we_PP determined_VBD the_DT relative_JJ numbers_NNS of_IN CD19+_NP B_NP cells_NNS and_CC CD8+_NP and_CC CD4+_NP T_NN cells_NNS within_IN spleens_NNS at_IN day_NN 14_CD p.i._NN by_IN fluorescence-activated_JJ cell_NN sorting_VBG (_( FACS_NP )_) analysis_NN ._SENT The_DT results_NNS indicated_VBD that_IN similar_JJ relative_JJ levels_NNS of_IN CD19+_NP and_CC CD8+_NP cell_NN populations_NNS were_VBD observed_VBN in_IN mice_NNS infected_VBN with_IN 76(WTR)_NP ,_, 76(RDeltaM2)_NP ,_, and_CC MHV-76_NP ._SENT However_RB ,_, while_IN there_EX was_VBD a_DT similar_JJ level_NN of_IN CD4+_NP cells_NNS in_IN mice_NNS infected_VBN with_IN 76(WTR)_NP and_CC 76(RDeltaM2)_NP ,_, the_DT number_NN of_IN this_DT subset_NN was_VBD significantly_RB elevated_VBN by_IN comparison_NN in_IN MHV-76-infected_JJ animals_NNS (_( P_NN =_SYM 0.007_CD by_IN t_NN test_NN )_) ._SENT In_IN a_DT similar_JJ fashion_NN ,_, the_DT activation_NN status_NN of_IN CD8+_NP and_CC CD4+_NP T_NN cells_NNS was_VBD determined_VBN by_IN coanalysis_NN of_IN the_DT levels_NNS of_IN CD62_JJ ligand_NN (_( CD62L_NP )_) expression_NN ,_, as_IN cells_NNS expressing_VBG low_JJ levels_NNS of_IN CD62L_NP (_( CD62Llow_NP )_) are_VBP more_RBR activated_VBN ._SENT As_IN illustrated_VBN in_IN Fig._NN ,_, there_EX was_VBD no_DT difference_NN in_IN the_DT numbers_NNS of_IN activated_VBN CD8+_NP T_NN cells_NNS in_IN mice_NNS infected_VBN with_IN any_DT of_IN the_DT three_CD viruses_NNS ._SENT However_RB ,_, there_EX was_VBD a_DT significantly_RB increased_VBN number_NN of_IN activated_VBN CD4+_JJ cells_NNS in_IN MHV-76-infected_JJ mice_NNS compared_VBN to_TO those_DT infected_JJ with_IN 76(WTR)_JJ and_CC 76(RDeltaM2)_JJ (_( P_NN =_SYM 0.007_CD by_IN t_NN test_NN )_) ._SENT The_DT relative_JJ increase_NN in_IN CD4+_NP CD62Llow_NP cells_NNS in_IN MHV-76-infected_JJ mice_NNS was_VBD similar_JJ to_TO the_DT relative_JJ increase_NN in_IN CD4+_NP cells_NNS ,_, indicating_VBG that_IN there_EX was_VBD no_DT difference_NN in_IN the_DT proportion_NN of_IN activated_VBN CD4+_JJ cells_NNS in_IN these_DT mice_NNS ._SENT Thus_RB ,_, mutation_NN in_IN M2_NP did_VBD not_RB affect_VB the_DT relative_JJ proportions_NNS or_CC activation_NN of_IN the_DT major_JJ spleen_NN cell_NN subsets_NNS that_WDT contribute_VBP to_TO MHV-68-induced_JJ lymphocytosis_NN ._SENT Latent_JJ virus_NN in_IN the_DT spleen_NN was_VBD first_RB measured_VBN at_IN various_JJ times_NNS p.i._JJ by_IN an_DT infective_JJ center_NN (_( IC_NP )_) assay_NN ._SENT In_IN mice_NNS infected_VBN with_IN 76(WTR)_JJ ,_, measurable_JJ latent_JJ (_( i.e._FW ,_, reactivated_VBN )_) virus_NN could_MD be_VB detected_VBN at_IN day_NN 7_CD p.i._NN and_CC peaked_VBN at_IN day_NN 14_CD p.i._NN ;_: by_IN day_NN 31_CD p.i._NNS a_DT level_NN of_IN approximately_RB 400_CD ICs_NN per_IN spleen_NN had_VBD been_VBN established_VBN ._SENT By_IN contrast_NN ,_, in_IN mice_NNS infected_VBN with_IN MHV-76_NP ,_, the_DT day_NN 14_CD spike_NN in_IN the_DT number_NN of_IN latently_RB infected_JJ cells_NNS characteristic_JJ of_IN wild-type_NP MHV-68/76(WTR)_NP was_VBD not_RB observed_VBN ,_, and_CC overall_RB the_DT amount_NN of_IN latently_RB infected_JJ cells_NNS detected_VBN was_VBD significantly_RB less_JJR (_( day_NN 14_CD ,_, P_NN <_SYM 0.001_CD )_) ._SENT MHV-76_NP ICs_NP were_VBD still_RB detectable_JJ at_IN day_NN 31_CD p.i._NN ,_, at_IN levels_NNS of_IN approximately_RB 50_CD per_IN spleen_NN ,_, i.e._FW ,_, one-eighth_NN of_IN that_DT obtained_VBN with_IN wild-type_JJ MHV-68_NP infection_NN ._SENT ICs_NNS in_IN 76(RDeltaM2)-infected_JJ mice_NNS were_VBD detectable_JJ at_IN day_NN 7_CD p.i._NN ,_, and_CC by_IN day_NN 14_CD latency_NN had_VBD been_VBN established_VBN at_IN a_DT relatively_RB constant_JJ level_NN of_IN approximately_RB 5,000_CD ICs_NN per_IN spleen_NN through_IN day_NN 31_CD p.i._NN At_IN day_NN 14_CD p.i._NN this_DT was_VBD a_DT significantly_RB lower_JJR level_NN than_IN that_WDT observed_VBD in_IN 76(WTR)-infected_JJ mice_NNS (_( P_NN <_SYM 0.001_CD )_) and_CC significantly_RB higher_JJR than_IN that_DT in_IN MHV-76_NP infection_NN (_( P_NN <_SYM 0.001_CD )_) ._SENT The_DT number_NN of_IN latently_RB infected_JJ cells_NNS did_VBD not_RB decrease_VB from_IN day_NN 14_CD through_IN 21_CD p.i._NN and_CC was_VBD 1_CD log_NN higher_JJR than_IN that_IN in_IN 76(WTR)_JJ infection_NN at_IN day_NN 31_CD p.i._NN (_( P_NN <_SYM 0.01_CD )_) ._SENT These_DT results_NNS indicated_VBD that_DT mutation_NN of_IN M2_NP severely_RB affected_VBD the_DT characteristic_JJ acute_JJ rise_NN in_IN ICs_NN (_( latently_RB infected_JJ cells_NNS )_) within_IN the_DT spleen_NN during_IN primary_JJ infection_NN and_CC ultimately_RB resulted_VBN in_IN an_DT increased_VBN level_NN of_IN latently_RB infected_JJ cells_NNS ._SENT It_PP should_MD be_VB noted_VBN that_IN we_PP did_VBD not_RB detect_VB preformed_JJ infectious_JJ virus_NN in_IN the_DT spleen_NN at_IN any_DT of_IN the_DT time_NN points_NNS analyzed_VBD ,_, which_WDT would_MD have_VB indicated_VBN a_DT significant_JJ presence_NN of_IN productively_RB infected_JJ cells_NNS ._SENT Thus_RB ,_, we_PP conclude_VBP that_IN the_DT results_NNS obtained_VBN with_IN the_DT IC_NP assay_NN represented_VBD reactivation_NN from_IN latent_JJ infection_NN ._SENT Because_IN the_DT mutation_NN in_IN M2_NP could_MD be_VB negatively_RB affecting_VBG the_DT ability_NN of_IN the_DT virus_NN to_TO reactivate_VB from_IN latency_NN ,_, also_RB resulting_VBG in_IN lower_JJR estimates_NNS of_IN latently_RB infected_JJ cells_NNS ,_, we_PP determined_VBD the_DT viral_JJ genome_NN copy_NN number_NN in_IN the_DT spleens_NNS of_IN infected_JJ mice_NNS by_IN quantitative_JJ fluorescent_JJ PCR_NP (_( QF-PCR_NP )_) ._SENT We_PP have_VBP previously_RB shown_VBN that_IN genome_NN copy_NN number_NN correlates_VBZ directly_RB with_IN the_DT number_NN of_IN latently_RB infected_VBN cells_NNS in_IN MHV-68-infected_JJ mice_NNS as_IN determined_VBN by_IN a_DT limiting_VBG dilution_NN reactivation_NN assay_NN ._SENT DNA_NP was_VBD therefore_RB isolated_VBN from_IN the_DT spleens_NNS of_IN mice_NNS at_IN days_NNS 14_CD (_( peak_NN of_IN lymphocytosis_NN )_) and_CC 46_CD p.i._NN and_CC subjected_VBN to_TO QF-PCR_NP ._SENT The_DT results_NNS indicated_VBD that_IN ,_, at_IN day_NN 14_CD p.i._NN with_IN all_DT three_CD viruses_NNS ,_, viral_JJ DNA_NP copy_NN number_NN was_VBD in_IN good_JJ agreement_NN with_IN the_DT IC_NP assay_NN ,_, i.e._FW ,_, DNA_NP copy_NN number_NN and_CC ICs_NN obtained_VBN from_IN mice_NNS infected_VBN with_IN MHV-76_NP and_CC 76(RDeltaM2)_NP were_VBD approximately_RB 10-fold_JJ lower_JJR than_IN in_IN 76(WTR)-infected_JJ mice_NNS (_( compare_NN Fig._NN )_) ._SENT A_DT positive_JJ correlation_NN between_IN copy_NN number_NN and_CC ICs_NN was_VBD also_RB observed_VBN at_IN day_NN 46_CD p.i._NNS However_RB ,_, the_DT number_NN of_IN viral_JJ genomes_NNS was_VBD 50-fold_NN higher_JJR in_IN 76(RDeltaM2)-infected_JJ mice_NNS than_IN in_IN 76(WTR)-infected_JJ mice_NNS ,_, a_DT difference_NN that_WDT was_VBD statistically_RB significant_JJ (_( P_NN <_SYM 0.0001_CD )_) as_IN determined_VBN by_IN the_DT Student_NP t_NN test_NN ._SENT By_IN contrast_NN ,_, in_IN our_PP$ IC_NP assay_NN ,_, the_DT number_NN of_IN latently_RB infected_VBN cells_NNS in_IN the_DT spleens_NNS of_IN 76(RDeltaM2)-infected_JJ mice_NNS was_VBD only_RB 10-fold_JJ higher_JJR than_IN that_DT in_IN the_DT 76(WTR)-infected_JJ mice_NNS ._SENT This_DT suggests_VBZ that_IN the_DT actual_JJ level_NN of_IN latency_NN established_VBN by_IN the_DT M2_JJ mutant_JJ virus_NN is_VBZ higher_JJR than_IN reactivable_JJ latency_NN ,_, indicating_VBG a_DT possible_JJ defect_NN in_IN the_DT ability_NN of_IN the_DT mutant_JJ virus_NN to_TO reactivate_VB from_IN latency_NN ._SENT To_TO confirm_VB that_IN the_DT effects_NNS on_IN latency_NN were_VBD due_JJ to_TO the_DT lesion_NN in_IN M2_NP ,_, we_PP generated_VBD a_DT second_JJ recombinant_JJ virus_NN with_IN a_DT 256-bp_JJ deletion_NN within_IN the_DT ORF_NP (_( coordinates_NN 4239_CD to_TO 4494_CD )_) ._SENT This_DT virus_NN had_VBD a_DT similar_JJ phenotype_NN in_IN vivo_RB as_RB 76(RDeltaM2)_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, the_DT effects_NNS seen_VBN were_VBD due_JJ to_TO the_DT mutation_NN of_IN M2_NP and_CC not_RB other_JJ secondary_JJ mutations_NNS in_IN the_DT viral_JJ genome_NN ._SENT Finally_RB ,_, to_TO confirm_VB that_IN the_DT observed_JJ properties_NNS of_IN the_DT 76(RDeltaM2)_JJ virus_NN were_VBD attributable_JJ to_TO the_DT frameshift_NN mutation_NN within_IN the_DT M2_JJ gene_NN ,_, we_PP determined_VBD the_DT sequence_NN of_IN the_DT M2_NP ORF_NP amplified_VBD from_IN DNA_NN extracted_VBN from_IN three_CD separate_JJ viral_JJ plaques_NNS resulting_VBG from_IN reactivation_NN from_IN three_CD different_JJ mice_NNS at_IN day_NN 14_CD p.i._NN with_IN 76(RDeltaM2_JJ )_) ._SENT The_DT results_NNS indicated_VBD that_IN ,_, in_IN all_DT cases_NNS ,_, the_DT only_JJ mutation_NN in_IN the_DT M2_NP ORF_NP was_VBD the_DT 4-bp_JJ deletion_NN that_IN we_PP had_VBD originally_RB introduced_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, we_PP found_VBD no_DT evidence_NN for_IN the_DT selection_NN of_IN M2_JJ revertant_JJ or_CC pseudorevertant_JJ viruses_NNS in_IN vivo_JJ and_CC concluded_VBD that_IN the_DT striking_JJ reduction_NN in_IN the_DT number_NN of_IN latently_RB infected_JJ cells_NNS observed_VBN at_IN day_NN 14_CD p.i._NN in_IN mice_NNS infected_VBN with_IN 76(RDeltaM2)_NP was_VBD indeed_RB a_DT consequence_NN of_IN the_DT mutation_NN within_IN M2_NP ._SENT A_DT decrease_NN in_IN the_DT peak_NN of_IN cells_NNS latently_RB infected_VBN with_IN M2_JJ mutant_JJ viruses_NNS was_VBD also_RB observed_VBN by_IN Jacoby_NP et_FW al._FW ._SENT This_DT fits_VBZ well_RB with_IN previous_JJ observations_NNS that_IN M2_NP is_VBZ expressed_VBN during_IN latency_NN and_CC that_IN the_DT peak_NN of_IN M2_JJ expression_NN in_IN the_DT spleen_NN appears_VBZ to_TO occur_VB around_IN day_NN 14_CD p.i_NNS ._SENT There_EX was_VBD ,_, however_RB ,_, a_DT significantly_RB greater_JJR number_NN of_IN latently_RB infected_JJ cells_NNS present_JJ in_IN the_DT spleens_NNS of_IN mice_NNS infected_VBN with_IN the_DT M2_JJ mutant_JJ virus_NN than_IN in_IN spleens_NNS of_IN mice_NNS infected_VBN with_IN MHV-76_NP at_IN day_NN 14_CD p.i._NN Because_IN MHV-76_NP lacks_VBZ M1_NP to_TO M4_NP and_CC the_DT vtRNAs_NNS ,_, one_CD or_CC more_JJR of_IN these_DT genes_NNS in_IN addition_NN to_TO M2_NP likely_RB contributes_VBZ to_TO the_DT transient_JJ spike_NN or_CC rise_NN in_IN latently_RB infected_JJ cells_NNS characteristically_RB observed_VBD at_IN this_DT point_NN following_VBG primary_JJ infection_NN ._SENT At_IN least_JJS part_NN of_IN this_DT is_VBZ due_JJ to_TO the_DT M3_NP protein_NN ,_, a_DT soluble_JJ chemokine_NN binding_VBG protein_NN ,_, since_IN viruses_NNS with_IN M3_NP deleted_VBD have_VBP a_DT defect_NN in_IN their_PP$ ability_NN to_TO cause_VB this_DT transient_JJ rise_NN in_IN latently_RB infected_VBN splenic_JJ lymphocytes_NNS ._SENT A_DT transient_JJ rise_NN in_IN latently_RB infected_JJ cells_NNS shortly_RB after_IN infection_NN is_VBZ seen_VBN with_IN other_JJ gammaherpesviruses_NNS such_JJ as_IN EBV_NP ._SENT The_DT biological_JJ function_NN of_IN this_DT is_VBZ not_RB known_VBN ,_, but_CC it_PP is_VBZ generally_RB believed_VBN to_TO promote_VB viral_JJ persistence_NN by_IN ensuring_VBG that_IN a_DT critical_JJ pool_NN of_IN latently_RB infected_VBN cells_NNS is_VBZ established_VBN prior_RB to_TO maturation_NN of_IN the_DT host_NN antiviral_JJ immunosurveillance_NN ._SENT Our_PP$ results_NNS suggest_VBP that_IN this_DT may_MD not_RB be_VB the_DT case_NN ,_, at_IN least_JJS for_IN MHV-68_NP ,_, since_IN both_DT 76(RDeltaM2)_NP and_CC MHV-76_NP are_VBP capable_JJ of_IN establishing_VBG long-term_JJ latency_NN ._SENT However_RB ,_, it_PP is_VBZ possible_JJ that_IN the_DT transient_JJ rise_NN in_IN latently_RB infected_JJ cells_NNS may_MD play_VB a_DT more_RBR critical_JJ role_NN ,_, such_JJ as_IN that_DT proposed_VBN in_IN EBV_NP infection_NN ,_, in_IN the_DT context_NN of_IN a_DT naturally_RB acquired_VBN MHV-68_NP infection_NN as_RB opposed_VBD to_TO one_CD that_WDT is_VBZ laboratory_NN acquired_VBN ._SENT Surprisingly_RB ,_, despite_IN the_DT dramatic_JJ reduction_NN in_IN the_DT number_NN of_IN latently_RB infected_JJ spleen_NN cells_NNS as_IN a_DT consequence_NN of_IN M2_JJ mutation_NN ,_, the_DT splenic_JJ lymphocytosis_NN that_WDT is_VBZ concomitant_JJ with_IN the_DT peak_JJ splenomegaly_NN at_IN day_NN 14_CD p.i._NNS was_VBD not_RB significantly_RB affected_VBN ._SENT Thus_RB ,_, for_IN the_DT first_JJ time_NN we_PP have_VBP been_VBN able_JJ to_TO separate_VB the_DT spike_NN in_IN latently_RB infected_VBN cells_NNS from_IN the_DT concurrent_JJ lymphocytosis_NN ,_, in_IN which_WDT all_DT spleen_NN lymphocyte_NN subsets_NNS are_VBP expanded_VBN ._SENT By_IN contrast_NN ,_, MHV-76_NP was_VBD severely_RB disabled_VBN in_IN its_PP$ ability_NN to_TO induce_VB lymphocytosis_NN ,_, strongly_RB suggesting_VBG that_IN one_CD or_CC more_JJR of_IN the_DT genes_NNS M1_NP ,_, M3_NP ,_, and_CC M4_NP or_CC the_DT vtRNAs_NNS are_VBP primarily_RB responsible_JJ for_IN this_DT phenomenon_NN ._SENT The_DT precise_JJ causes_NNS of_IN the_DT transient_JJ lymphocytosis_NN and_CC rise_NN in_IN latently_RB infected_JJ cells_NNS are_VBP unclear_JJ ,_, but_CC it_PP has_VBZ been_VBN assumed_VBN that_IN they_PP are_VBP interdependent_JJ ._SENT Specifically_RB ,_, in_IN addition_NN to_TO their_PP$ temporal_JJ overlap_VBP during_IN primary_JJ infection_NN ,_, both_CC are_VBP dependent_JJ upon_IN latently_RB infected_JJ B_NN cells_NNS and_CC CD4+_JJ T_NN cells_NNS ._SENT This_DT led_VBD to_TO two_CD alternative_NN hypotheses_NNS ._SENT The_DT first_JJ is_VBZ that_IN the_DT virus_NN drives_VBZ the_DT expansion_NN of_IN latently_RB infected_JJ B_NN cells_NNS and_CC that_IN CD4+_NP and_CC CD8+_NP T-cell_NN expansion_NN is_VBZ in_IN reaction_NN to_TO this_DT ._SENT The_DT second_NN is_VBZ that_IN virus_NN infection_NN causes_VBZ activation_NN and_CC expansion_NN of_IN CD4+_NP T_NN cells_NNS ,_, which_WDT in_IN turn_NN drive_VBP the_DT expansion_NN of_IN latently_RB infected_JJ B_NN cells_NNS and_CC CD8+_JJ T_NN cells_NNS ._SENT In_IN the_DT light_NN of_IN our_PP$ present_JJ results_NNS ,_, however_RB ,_, it_PP seems_VBZ likely_RB that_IN an_DT alternative_JJ mechanism_NN is_VBZ operating_VBG ,_, namely_RB ,_, that_IN first_RB the_DT transient_JJ expansion_NN of_IN latently_RB infected_JJ cells_NNS and_CC splenic_JJ lymphocytosis_NN are_VBP not_RB dependent_JJ upon_IN one_CD another_DT ;_: second_JJ ,_, transient_JJ expansion_NN of_IN the_DT number_NN of_IN latently_RB infected_VBN cells_NNS is_VBZ virus_NN driven_VBN ,_, with_IN M2_NP playing_VBG a_DT major_JJ role_NN ;_: and_CC third_JJ ,_, the_DT expansion_NN of_IN noninfected_JJ B_NP cells_NNS ,_, and_CC CD4+_NP and_CC CD8+_NP T_NN cells_NNS ,_, appears_VBZ to_TO be_VB in_IN response_NN to_TO latently_RB infected_JJ cells_NNS ,_, but_CC this_DT is_VBZ dependent_JJ upon_IN neither_DT high_JJ levels_NNS of_IN these_DT cells_NNS nor_CC M2_JJ expression_NN ._SENT Finally_RB ,_, as_IN indicated_VBN above_JJ ,_, other_JJ viral_JJ genes_NNS not_RB present_JJ in_IN MHV-76_NP are_VBP key_JJ to_TO the_DT expansion_NN of_IN spleen_NN lymphocyte_NN number_NN ._SENT Given_VBN that_IN M2_NP was_VBD required_VBN for_IN the_DT expansion_NN of_IN latently_RB infected_VBN cells_NNS within_IN the_DT spleen_NN during_IN acute_JJ infection_NN ,_, it_PP was_VBD somewhat_RB surprising_JJ that_IN mutation_NN of_IN M2_NP did_VBD not_RB negatively_RB affect_VB the_DT establishment_NN of_IN long-term_JJ latency_NN ._SENT This_DT is_VBZ supported_VBN by_IN similar_JJ observations_NNS obtained_VBN with_IN other_JJ M2_JJ mutants_NNS and_CC with_IN MHV-76_NP ._SENT Interestingly_RB ,_, the_DT level_NN of_IN both_DT reactivable_JJ latency_NN and_CC latent_JJ genomes_NNS maintained_VBD long-term_JJ by_IN our_PP$ M2_JJ mutant_NN in_IN the_DT spleen_NN was_VBD significantly_RB higher_JJR than_IN that_DT for_IN either_DT wild-type_NN virus_NN or_CC MHV-76_NP ._SENT An_DT elevation_NN of_IN the_DT level_NN of_IN genome-positive_JJ cells_NNS in_IN the_DT spleen_NN after_IN peritoneal_JJ infection_NN was_VBD also_RB observed_VBN by_IN Jacoby_NP et_FW al._FW ,_, using_VBG a_DT similar_JJ mutation_NN in_IN M2_NP (_( introduction_NN of_IN a_DT stop_NN codon_NN )_) ._SENT It_PP is_VBZ possible_JJ ,_, therefore_RB ,_, in_IN a_DT way_NN analogous_JJ to_TO EBV_NP LMP-2A_NP ,_, that_WDT M2_JJ functions_NNS in_IN part_NN by_IN inhibiting_VBG or_CC preventing_VBG the_DT overexpansion_NN of_IN virus-infected_JJ cells_NNS within_IN the_DT host_NN ._SENT Since_IN this_DT expansion_NN is_VBZ not_RB observed_VBN in_IN mice_NNS infected_VBN with_IN MHV-76_NP ,_, this_DT effect_NN is_VBZ most_RBS likely_JJ dependent_NN upon_IN other_JJ gene_NN products_NNS present_JJ at_IN the_DT left_VBN end_NN of_IN the_DT MHV-68_NP genome_NN ._SENT positive_JJ mononucleosis_NN ._SENT :_: To_TO assess_VB whether_IN the_DT MHV-68-induced_JJ mononucleosis_NN is_VBZ in_IN response_NN to_TO the_DT M2_JJ gene_NN product_NN ,_, C57BL/6_NP mice_NNS were_VBD infected_VBN with_IN MHV-76_NP ,_, 76(WTR)_NP ,_, and_CC 76(RDeltaM2)_NP ,_, and_CC their_PP$ peripheral_JJ blood_NN was_VBD assayed_VBN by_IN FACS_NP at_IN day_NN 35_CD p.i._NNS as_RB described_VBD previously_RB ._SENT Two_CD parameters_NNS of_IN mononucleosis_NN were_VBD measured_VBN :_: the_DT presence_NN of_IN activated_VBN CD8+_JJ lymphocytes_NNS (_( CD62Llow_NP )_) and_CC the_DT levels_NNS of_IN Vbeta4+_NP CD8+_NP T_NN cells_NNS ._SENT As_IN shown_VBN by_IN the_DT representative_JJ data_NNS presented_VBN in_IN Fig._NN ,_, the_DT pattern_NN of_IN CD62L_NP staining_VBG was_VBD similar_JJ regardless_RB of_IN the_DT strain_NN of_IN infecting_VBG virus_NN ._SENT Specifically_RB ,_, in_IN each_DT case_NN the_DT majority_NN (_( 99_CD %_NN )_) of_IN CD8+_NP T_NN cells_NNS expressed_VBD low_JJ levels_NNS of_IN CD62L_NP ._SENT By_IN contrast_NN ,_, mice_NNS infected_VBN with_IN either_DT 76(WTR)_NP or_CC 76(RDeltaM2)_NP had_VBD elevated_VBN levels_NNS of_IN Vbeta4+_NP CD8+_NP cells_NNS (_( 24_CD and_CC 22_CD %_NN ,_, respectively_RB )_) relative_JJ to_TO mice_NNS infected_VBN with_IN MHV-76_NP ,_, which_WDT as_RB expected_VBD had_VBD relatively_RB normal_JJ levels_NNS (_( 4_CD %_NN )_) of_IN Vbeta4+_NP CD8+_NP T_NN cells_NNS ._SENT Thus_RB ,_, the_DT mutation_NN in_IN M2_NP affected_VBN neither_CC the_DT presence_NN of_IN elevated_JJ levels_NNS of_IN activated_VBN CD8+_NP T_NN cells_NNS in_IN the_DT periphery_NN nor_CC the_DT high_JJ level_NN of_IN Vbeta4+_NP CD8+_NP cells_NNS in_IN this_DT population_NN ._SENT Thus_RB ,_, MHV-68-induced_JJ mononucleosis_NN is_VBZ dependent_JJ on_IN a_DT gene_NN other_JJ than_IN M2_NP that_WDT is_VBZ present_JJ within_IN the_DT leftmost_JJ 9.5_CD kbp_NN of_IN the_DT unique_JJ portion_NN of_IN the_DT MHV-68_NP genome_NN ,_, i.e._FW ,_, that_IN deleted_VBN in_IN MHV-76_NP ._SENT Like_IN lymphocytosis_NN in_IN the_DT spleen_NN ,_, the_DT viral_JJ factors_NNS responsible_JJ for_IN the_DT generation_NN of_IN either_CC the_DT peripheral_JJ CD8+_NP T-cell_NN mononucleosis_NN or_CC the_DT abnormal_JJ expansion_NN of_IN Vbeta4_NP TCR+_NP cells_NNS within_IN this_DT population_NN have_VBP not_RB been_VBN identified_VBN ._SENT However_RB ,_, like_IN the_DT transient_JJ expansion_NN of_IN spleen_NN cells_NNS ,_, Vbeta4_NP TCR+_NP CD8+_NP expansion_NN is_VBZ dependent_JJ upon_IN the_DT presence_NN of_IN MHV-68-infected_NP B_NP cells_NNS and_CC CD40_JJ ligand-dependent_JJ CD4+_NP T-cell_NN help_NN ._SENT The_DT mutation_NN in_IN M2_NP affected_VBD neither_DT mononucleosis_NN nor_CC expansion_NN of_IN Vbeta4+_NP T_NN cells_NNS ._SENT However_RB ,_, while_IN MHV-76_NP induced_VBD peripheral_JJ mononucleosis_NN ,_, it_PP did_VBD not_RB promote_VB expansion_NN of_IN Vbeta4+_NP T_NN cells_NNS ._SENT This_DT indicates_VBZ that_IN specific_JJ viral_JJ products_NNS are_VBP required_VBN for_IN Vbeta4+_NP T-cell_NN expansion_NN and_CC that_IN they_PP reside_VBP within_IN the_DT deletion_NN present_NN in_IN MHV-76_NP ,_, excluding_VBG M2_NP ._SENT Our_PP$ previous_JJ analyses_NNS have_VBP shown_VBN that_IN M2_NP mRNA_NP is_VBZ actively_RB expressed_VBN at_IN day_NN 14_CD p.i._NN in_IN the_DT spleens_NNS of_IN mice_NNS infected_VBN with_IN MHV-68_NP and_CC is_VBZ detectable_JJ sporadically_RB in_IN splenic_JJ B_NP cells_NNS at_IN later_JJR time_NN points_NNS p.i._JJ ._SENT In_IN addition_NN to_TO B_NP cells_NNS ,_, MHV-68_NP also_RB infects_VBZ splenic_JJ macrophages_NNS and_CC dendritic_JJ cells_NNS ._SENT To_TO ascertain_VB in_IN which_WDT spleen_NN cell_NN type(s)_NN M2_NP is_VBZ expressed_VBN ,_, C57BL/6_NP mice_NNS were_VBD infected_VBN intranasally_RB with_IN MHV-68_NP ._SENT B_NP cells_NNS (_( total_NN ,_, activated_VBN ,_, and_CC resting_JJ )_) ,_, macrophages_NNS ,_, and_CC dendritic_JJ cells_NNS were_VBD then_RB isolated_VBN by_IN FACS_NP from_IN the_DT spleens_NNS at_IN day_NN 14_CD p.i._NN ,_, and_CC total_JJ RNA_NP extracted_VBD from_IN these_DT cells_NNS was_VBD subjected_VBN to_TO nested_VBN reverse_JJ transcription-PCR_NN (_( RT-PCR_NP )_) as_RB described_VBD previously_RB ._SENT In_IN addition_NN to_TO M2_NP ,_, the_DT expression_NN of_IN the_DT MHV-68_NP M3_NP and_CC cellular_JJ beta-actin_NN mRNAs_NNS were_VBD analyzed_VBN using_VBG primers_NNS shown_VBN in_IN Table_NP ._SENT M3_NP was_VBD chosen_VBN because_IN it_PP is_VBZ also_RB characteristically_RB expressed_VBN in_IN the_DT spleen_NN at_IN this_DT time_NN point_NN ;_: detection_NN of_IN the_DT beta-actin_NN mRNA_NN served_VBN as_IN an_DT indicator_NN of_IN mRNA_NN integrity_NN and_CC a_DT positive_JJ control_NN for_IN amplification_NN ._SENT In_IN serial_JJ dilution_NN assays_NNS ,_, our_PP$ RT-PCR_NP assay_NN was_VBD able_JJ to_TO detect_VB M2_JJ mRNA_NN in_IN as_RB few_JJ as_IN one_CD S11_JJ cell_NN in_IN 105_CD MHV-68-negative_JJ cells_NNS (_( BJAB_NP B-lymphoma_NP cells_NNS ;_: data_NNS not_RB shown_VBN )_) ._SENT S11_NP is_VBZ a_DT latently_RB infected_JJ murine_JJ B-cell_NN tumor_NN line_NN that_WDT expresses_VBZ M2_JJ mRNA_NN in_IN virtually_RB all_DT cells_NNS ,_, and_CC thus_RB the_DT level_NN of_IN M2_JJ expression_NN in_IN these_DT cells_NNS is_VBZ likely_JJ to_TO be_VB an_DT accurate_JJ representation_NN of_IN its_PP$ expression_NN in_IN latently_RB infected_VBN cells_NNS in_IN vivo_RB ._SENT Additionally_RB ,_, upon_IN spiking_VBG cDNA_NNS synthesized_VBN from_IN the_DT total_JJ RNA_NP of_IN MHV-68-negative_JJ cells_NNS with_IN a_DT full-length_JJ M2_JJ cDNA_NN ,_, we_PP determined_VBD that_IN the_DT sensitivity_NN of_IN our_PP$ PCR_NP assay_NN was_VBD sufficient_JJ to_TO detect_VB between_IN one_CD and_CC five_CD copies_NNS of_IN the_DT M2_JJ target_NN (_( data_NNS not_RB shown_VBN )_) ._SENT To_TO detect_VB gene_NN expression_NN in_IN spleen_NN cell_NN subsets_NNS ,_, RNA_NP from_IN a_DT total_NN of_IN at_IN least_JJS three_CD independent_JJ sorts_NNS for_IN each_DT cell_NN type_NN was_VBD analyzed_VBN ._SENT As_IN shown_VBN in_IN Table_NP ,_, whereas_IN M3_NP transcripts_NNS were_VBD detected_VBN in_IN all_DT cell_NN subsets_NNS analyzed_VBD ,_, M2_NP mRNA_NP was_VBD detected_VBN only_RB in_IN B_NP cells_NNS ,_, both_CC activated_VBN and_CC resting_JJ ._SENT beta-Actin_NN mRNA_NNS was_VBD equivalently_RB amplified_VBN in_IN all_DT RNA_NP samples_NNS analyzed_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT Our_PP$ other_JJ studies_NNS have_VBP shown_VBN that_IN the_DT frequency_NN of_IN infection_NN within_IN each_DT cell_NN subset_NN (_( determined_VBN by_IN limiting_VBG dilution_NN analysis-PCR_NN )_) ,_, though_IN highest_JJS in_IN activated_VBN B_NN cells_NNS ,_, is_VBZ well_RB within_IN the_DT level_NN of_IN detection_NN of_IN this_DT assay_NN (_( 10-5_CD )_) ,_, as_RB described_VBN above_IN ._SENT Thus_RB ,_, these_DT data_NNS strongly_RB suggest_VBP that_IN M2_JJ expression_NN in_IN the_DT spleen_NN is_VBZ B_NP cell_NN specific_NN ._SENT Previous_JJ analyses_NNS of_IN M2_NP have_VBP shown_VBN that_IN it_PP is_VBZ expressed_VBN within_IN the_DT latently_RB infected_JJ S11_NP B-cell_NN line_NN in_IN vitro_NN and_CC during_IN latency_NN in_IN vivo_RB ,_, most_RBS abundantly_RB (_( as_RB determined_VBN by_IN RT-PCR_NP )_) during_IN the_DT peak_NN of_IN lymphocytosis_NN in_IN the_DT spleen_NN at_IN day_NN 14_CD p.i_NNS ._SENT Here_RB ,_, we_PP extend_VBP these_DT analyses_NNS by_IN showing_VBG that_IN M2_NP is_VBZ expressed_VBN predominantly_RB ,_, if_IN not_RB solely_RB ,_, within_IN B_NP cells_NNS and_CC not_RB in_IN splenic_JJ macrophages_NNS and_CC dendritic_JJ cells_NNS that_WDT also_RB harbor_VBP latent_JJ virus_NN ._SENT A_DT previous_JJ report_NN of_IN M2_JJ expression_NN in_IN spleen_NN and_CC peritoneal_JJ exudate_NN cells_NNS following_VBG intraperitoneal_JJ inoculation_NN of_IN muMT_JJ knockout_NN mice_NNS ,_, which_WDT fail_VBP to_TO develop_VB mature_JJ B_NN cells_NNS due_JJ to_TO an_DT inability_NN to_TO express_VB the_DT immunoglobulin_NN M_NN heavy_JJ chain_NN (_( mum_JJ )_) ,_, would_MD seem_VB to_TO be_VB inconsistent_JJ with_IN our_PP$ finding_NN here_RB of_IN B-cell-restricted_JJ expression_NN of_IN M2_NP ._SENT However_RB ,_, recent_JJ findings_NNS indicate_VBP that_IN muMT_NN mice_NNS do_VBP indeed_RB generate_VB B_NP cells_NNS ,_, through_IN an_DT mum-independent_JJ pathway_NN ,_, that_WDT specifically_RB produce_VBP immunoglobulin_NN A_DT ._SENT It_PP is_VBZ possible_JJ ,_, therefore_RB ,_, that_IN such_JJ B_NP cells_NNS were_VBD the_DT source_NN of_IN M2_JJ expression_NN in_IN MHV-68-infected_JJ muMT_NN mice_NNS ._SENT The_DT predicted_VBN amino_NN acid_NN sequence_NN of_IN the_DT M2_NP protein_NN lacks_VBZ sufficient_JJ homology_NN to_TO any_DT known_VBN protein_NN or_CC functional_JJ motif_NN that_WDT would_MD suggest_VB its_PP$ role_NN during_IN MHV-68_NP infection_NN ._SENT Therefore_RB ,_, as_IN a_DT first_JJ step_NN in_IN defining_VBG M2_JJ function_NN ,_, we_PP transiently_RB expressed_VBD it_PP within_IN mouse_NN A20_NP B_NP cells_NNS ._SENT Because_IN of_IN the_DT lack_NN of_IN an_DT adequate_JJ M2-specific_JJ antibody_NN ,_, M2_NP was_VBD expressed_VBN as_IN either_CC an_DT N-_NP or_CC C-terminal_NP fusion_NN with_IN enhanced_JJ green_JJ fluorescent_JJ protein_NN (_( EGFP_NP )_) by_IN using_VBG the_DT vectors_NNS pEGFP-C1_JJ and_CC pEGFP-N1_JJ (_( Clontech_NP )_) to_TO aid_VB in_IN its_PP$ detection_NN ._SENT Immunoblot_NN analysis_NN of_IN transfected_JJ A20_NP cells_NNS revealed_VBD the_DT presence_NN of_IN a_DT novel_JJ protein_NN of_IN similar60_JJ kDa_NN in_IN the_DT lysates_NNS of_IN those_DT cells_NNS transfected_VBN with_IN an_DT expression_NN vector_NN encoding_VBG either_CC the_DT N-_NP or_CC C-terminal_NP EGFP-M2_NP fusion_NN protein_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Accounting_NN for_IN the_DT mass_NN of_IN the_DT EGFPs_NP ,_, the_DT molecular_JJ mass_NN of_IN M2_NP is_VBZ similar30_JJ kDa_NN ._SENT This_DT was_VBD in_IN good_JJ agreement_NN with_IN the_DT size_NN of_IN a_DT hemagglutinin-tagged_JJ version_NN of_IN M2_NP stably_RB expressed_VBD in_IN A20_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) and_CC previously_RB reported_VBD unpublished_JJ observations_NNS by_IN others_NNS ._SENT Of_IN particular_JJ note_NN was_VBD the_DT observation_NN that_IN the_DT molecular_JJ mass_NN of_IN M2_NP in_IN the_DT fusion_NN was_VBD considerably_RB greater_JJR than_IN its_PP$ predicted_VBN molecular_JJ mass_NN of_IN 22_CD kDa_NN ._SENT The_DT molecular_JJ mass_NN of_IN the_DT protein_NN by_IN in_IN vitro_NN transcription_NN and_CC translation_NN analysis_NN was_VBD 26_CD kDa_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, the_DT molecular_JJ mass_NN of_IN 30_CD kDa_NN for_IN native_JJ M2_NP is_VBZ most_RBS likely_RB due_JJ to_TO a_DT combination_NN of_IN an_DT aberrant_JJ migration_NN of_IN the_DT unmodified_JJ polypeptide_NN backbone_NN in_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN and_CC a_DT contribution_NN of_IN approximately_RB 4_CD kDa_NN by_IN posttranslational_JJ modification(s_NNS )_) ._SENT To_TO determine_VB the_DT subcellular_JJ localization_NN of_IN the_DT M2_JJ protein_NN ,_, transiently_RB expressed_VBD EGFP-M2_NP was_VBD examined_VBN in_IN A20_NP cells_NNS at_IN 24_CD h_NN posttransfection_NN by_IN confocal_JJ microscopy_NN with_IN a_DT Leica_NP TCSNT_NP confocal_JJ system_NN ._SENT In_IN some_DT experiments_NNS ,_, cells_NNS were_VBD fixed_VBN in_IN 4_CD %_NN (_( wt/vol_NN )_) paraformaldehyde_NN and_CC stained_VBN with_IN either_DT propidium_NN iodide_NN (_( PI_NP ;_: in_IN phosphate-buffered_JJ saline_NN containing_VBG 10_CD mug_NN of_IN RNase_NP A_NP [_SYM Qiagen_NP ]_SYM and_CC 1_CD mug_NN of_IN PI_NP [_SYM Molecular_JJ Probes_NNS ]_SYM per_IN ml_NN for_IN 30_CD min_NN at_IN 37C_JJ in_IN the_DT dark_NN )_) to_TO label_VB DNA_NN or_CC tetramethyl_NN rhodamine_NN isocyanate_NN (TRITC)-labeled_VBD reagents_NNS to_TO detect_VB specific_JJ cellular_JJ markers_NNS ._SENT Cells_NNS were_VBD observed_VBN using_VBG a_DT combination_NN of_IN laser_NN light_NN wavelength_NN and_CC band_NN filter_NN specific_JJ for_IN EGFP_NP (_( 488_CD and_CC 525/50_CD nm_NN )_) or_CC PI-TRITC_NP (_( 568_CD and_CC 600/30_CD nm_NN )_) ._SENT Image_NN analysis_NN was_VBD then_RB used_VBN to_TO form_VB a_DT picture_NN with_IN the_DT resulting_VBG two_CD images_NNS overlaid_VBN ._SENT Representative_NN results_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Cells_NNS transfected_VBN with_IN empty_JJ vector_NN (_( pEGFP-C1_JJ )_) displayed_VBD a_DT diffuse_JJ pattern_NN of_IN EGFP-specific_JJ fluorescence_NN that_WDT was_VBD present_JJ throughout_IN the_DT cytoplasm_NN and_CC nucleus_NN as_IN evidenced_VBN by_IN the_DT covisualization_NN of_IN EGFP_NP and_CC PI_NP ._SENT In_IN cells_NNS transfected_VBN with_IN pEGFP-C1/M2_NN the_DT EGFP-M2-specific_JJ fluorescence_NN was_VBD primarily_RB localized_VBN in_IN patches_NNS near_IN the_DT cell_NN margins_NNS and_CC in_IN the_DT nucleus_NN ,_, as_RB well_RB as_RB diffusely_RB at_IN a_DT lower_JJR intensity_NN throughout_IN the_DT nucleus_NN and_CC cytoplasm_NN ._SENT However_RB ,_, nuclear_JJ staining_VBG was_VBD not_RB universal_JJ and_CC there_RB appeared_VBD to_TO be_VB little_JJ crossover_NN between_IN the_DT EGFP-M2_NP and_CC PI_NP fluorescence_NN ._SENT A_DT similar_JJ pattern_NN of_IN staining_VBG was_VBD seen_VBN with_IN the_DT C-terminal_JJ fusion_NN protein_NN encoded_VBN by_IN pEGFP-N1/M2_NN and_CC when_WRB a_DT hemagglutinin_NN epitope-tagged_JJ molecule_NN was_VBD expressed_VBN in_IN the_DT same_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS were_VBD consistent_JJ with_IN M2_NP being_VBG principally_RB localized_VBN in_IN patches_NNS at_IN or_CC near_IN the_DT plasma_NN membrane_NN and_CC within_IN areas_NNS in_IN the_DT nucleus_NN that_WDT did_VBD not_RB contain_VB chromatin_NN ._SENT Because_IN the_DT cytoplasm_NN in_IN B_NP cells_NNS is_VBZ small_JJ and_CC it_PP is_VBZ thus_RB often_RB hard_JJ to_TO distinguish_VB membrane_NN and_CC cytoplasmic_JJ fluorescence_NN ,_, we_PP immunostained_VBD pEGFP-C1/M2-transfected_JJ cells_NNS with_IN TRITC-labeled_JJ anti-MHC_NN class_NN II_NP (_( monoclonal_NN antibody_NN SW_NP 73.2_CD )_) ._SENT MHC_NP class_NN II_NP glycoprotein_NN molecules_NNS are_VBP principally_RB localized_VBN to_TO the_DT plasma_NN membrane_NN of_IN B_NP cells_NNS ._SENT The_DT EGFP-M2-specific_JJ fluorescence_NN was_VBD as_RB observed_VBN previously_RB ,_, and_CC a_DT proportion_NN of_IN the_DT patches_NNS of_IN EGFP-M2_NP clearly_RB colocalized_VBD with_IN MHC_NP class_NN II_NP ,_, as_RB evidenced_VBN by_IN yellow_JJ staining_VBG when_WRB the_DT two_CD images_NNS were_VBD overlaid_VBN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN when_WRB anti-CD19_NP (_( another_DT B-cell_NN surface_NN marker_NN )_) was_VBD used_VBN instead_RB of_IN anti-MHC_NN class_NN II_NP (_( data_NN not_RB shown_VBN )_) ._SENT Additionally_RB ,_, no_DT colocalization_NN was_VBD observed_VBN between_IN EGFP-M2_NP and_CC BODIPY_NP ceramide_NN (_( a_DT marker_NN for_IN the_DT Golgi_NP apparatus_NN )_) or_CC LysoTracker_NP Red_NP DND-99_NP (_( a_DT marker_NN for_IN lysosomes_NNS )_) (_( data_NNS not_RB shown_VBN )_) ._SENT Thus_RB ,_, the_DT above_JJ results_NNS are_VBP consistent_JJ with_IN a_DT proportion_NN of_IN the_DT M2_JJ protein_NN being_VBG cytoplasmic_JJ and_CC a_DT proportion_NN being_VBG localized_VBN in_IN patches_NNS either_CC at_IN or_CC extremely_RB close_VB to_TO the_DT plasma_NN membrane_NN ._SENT Our_PP$ M2_JJ expression_NN data_NNS suggest_VBP that_IN the_DT effects_NNS of_IN mutation_NN of_IN M2_NP as_RB discussed_VBD above_RB are_VBP B_NP cell_NN specific_NN ._SENT Thus_RB ,_, in_IN some_DT respects_NNS ,_, M2_JJ function_NN may_MD be_VB analogous_JJ to_TO the_DT perceived_VBN collective_JJ function_NN of_IN the_DT EBV_NP growth_NN program_NN of_IN latency_NN gene_NN expression_NN (_( which_WDT includes_VBZ several_JJ B-cell-restricted_JJ genes_NNS )_) :_: principally_RB ,_, to_TO drive_VB the_DT rapid_JJ expansion_NN of_IN infected_JJ cells_NNS to_TO establish_VB a_DT critical_JJ pool_NN of_IN latently_RB infected_JJ cells_NNS ._SENT The_DT function_NN of_IN M2_NP ,_, however_RB ,_, remains_VBZ enigmatic_JJ ._SENT Preliminary_JJ biochemical_JJ analyses_NNS failed_VBD to_TO demonstrate_VB any_DT posttranslational_JJ modification_NN of_IN the_DT protein_NN that_WDT might_MD have_VB shed_VBN light_NN on_IN this_DT problem_NN ._SENT While_IN the_DT apparent_JJ effects_NNS of_IN M2_JJ expression_NN in_IN the_DT spleen_NN and_CC its_PP$ localization_NN to_TO the_DT cytoplasm_NN and_CC plasma_NN membrane_NN may_MD argue_VB for_IN a_DT role_NN in_IN cell_NN signaling_VBG ,_, the_DT precise_JJ function_NN of_IN M2_NP and_CC its_PP$ specific_JJ role_NN in_IN MHV-68_NP latency_NN remain_VBP to_TO be_VB determined_VBN ._SENT Targeted_JJ mutation_NN of_IN the_DT M2_JJ gene_NN in_IN MHV_NP ._SENT Targeted_JJ mutation_NN of_IN the_DT M2_JJ gene_NN in_IN MHV_NP ._SENT (_( A_NP )_) Schematic_NP representation_NN of_IN the_DT left_VBN end_NN of_IN the_DT MHV-68_NP genome_NN ._SENT ORFs_NNS are_VBP shown_VBN as_IN shaded_JJ arrows_NNS ,_, and_CC the_DT eight_CD vtRNAs_NNS are_VBP shown_VBN as_IN small_JJ arrowheads_NNS ._SENT TRs_NP ,_, terminal_JJ repeat_NN elements_NNS ._SENT Note_NN that_IN the_DT M2_NP ORF_NP is_VBZ within_IN the_DT second_JJ exon_NN of_IN the_DT M2_JJ mRNA_NN ._SENT The_DT positions_NNS of_IN the_DT HincII_NP restriction_NN sites_NNS (_( genomic_JJ coordinates_NN given_VBN )_) used_VBD to_TO evaluate_VB recombinant_JJ virus_NN DNA_NN are_VBP shown_VBN above_IN ._SENT The_DT position_NN of_IN the_DT M2_JJ probe_NN used_VBN in_IN Southern_JJ analysis_NN of_IN viral_JJ DNA_NN is_VBZ shown_VBN below_RB ._SENT (_( B_NP )_) Sequence_NN of_IN the_DT M2_JJ gene_NN and_CC protein_NN surrounding_VBG the_DT site_NN of_IN the_DT introduced_VBN 4-bp_JJ deletion_NN (_( shaded_JJ box_NN )_) at_IN the_DT unique_JJ SalI_NP restriction_NN site_NN ._SENT The_DT amino_NN acid_NN sequence_NN of_IN the_DT known_VBN cytotoxic_JJ T-lymphocyte_NN epitope_NN within_IN M2_NP is_VBZ shown_VBN in_IN underlined_VBN italic_NN boldface_JJ ._SENT (_( C_LS )_) Southern_JJ blot_NN analysis_NN of_IN DNA_NN isolated_VBN from_IN BHK-21_JJ cells_NNS infected_VBN with_IN MHV-76_NP ,_, 76(WTR)_NP ,_, or_CC 76(RDeltaM2)_JJ and_CC digested_VBN with_IN HincII_NP ._SENT The_DT blot_NN was_VBD hybridized_VBN to_TO a_DT 32P-labeled_JJ M2_NP DNA_NP probe_NN (_( nucleotides_NNS 4000_CD to_TO 4606_CD )_) ._SENT The_DT positions_NNS of_IN molecular_JJ size_NN markers_NNS (_( in_IN base_NN pairs_NNS )_) within_IN the_DT gel_NN are_VBP shown_VBN to_TO the_DT left_VBN 